A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs (HCV PMS)

AbbVie

Status: Completed

Conditions: Hepatitis C Virus (HCV)

Study type: Observational

Funder types: Industry

Identifiers

NCT03201718

P16-666

Details and patient eligibility

About

Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean patients with Hepatitis C.

Enrollment: 505 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with type C hepatitis
• Participants prescribed Viekira/Exviera in accordance with approved local label

Exclusion criteria

• None

Trial design

505 participants in 1 patient group

Hepatitis C

Description:

Participants with Hepatitis C receiving Viekira/Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) for 12 or 24 weeks.